CLSA Pres. & CEO Sara Radcliffe pens an op-ed in the San Jose Mercury News calling on Congress to repeal the Independent Payment Advisory Board (IPAB), a controversial advisory board enacted as part of the ACA, which threatens seniors’ care and could harm biomedical innovation by reducing incentives for investment in new research and product development.
CLSA’s Jenny Carey and EveryLife Foundation for Rare Diseases’ Julia Jenkins pen an op-ed in The Hill on the need enact sound public policies that help tackle the more than 7,000 rare diseases affecting 30 million people, more than half of whom are children.
CLSA Pres. & CEO Sara Radcliffe pens a letter to the editor of The Sacramento Bee responding to their Aug. 11 editorial endorsement of SB 1010, flawed legislation that could enable speculative buying of medicines, creating shortages and leading to growth in “gray markets” where medicine is sold to the highest bidder.
Caroline Loewy, a mother and parent advocate for rare diseases, pens an op-ed in the East Bay Times calling on the policymakers to invest in and promote medical innovation.
CLSA Pres. & CEO Sara Radcliffe pens an op-ed in The Sacramento Bee on the pitfalls of SB 1010, flawed legislation that could hinder patient access to care in California.
Dr. R. Swamy Venturupalli, a former Clinical Chief of Rheumatology at Cedars Sinai Medical Center and a leader in the field of genetic and molecular causes of autoimmune diseases, pens an op-ed in The Fresno Bee highlighting the need to be aware of the potential and unintended consequences when it comes to healthcare decisions, including protecting patients, encouraging innovation and ensuring life-saving medications are available to all who need them.
CLSA Pres. & CEO Sara Radcliffe pens a letter to the editor of the Los Angeles Times, highlighting the flaws of SB 1010, which creates additional red tape and leads to gray-market prescription drug stockpiling.
Bridget Hood, a patient advocate, pens an op-ed in The Orange County Register calling on elected officials in Sacramento and Washington D.C. to not make any kinds of policy decisions that could weaken access or slow down medical innovation, but instead, help turn the hope for miracle medicines into a reality by moving medical innovation forward.
CLSA’s own Eve Bukowski, our VP of State Government Relations and a cancer fighter pens a letter to the editor of CALMatters, which pushes back on a recent article in CALMatters (“California Searches for Prescription to Treat Rising Drug Costs,” April 10) that suggests the state simply could not afford to treat poor patients who need life-saving medicines to treat their serious or even life-threatening illness.
A Letter to the Editor authored by CLSA President & CEO Sara Radcliffe was published in the Los Angeles Daily News. This letter responds to an opinion piece originally published February 18 by Heidi Sanborn, executive director of the California Product Stewardship Council, a key group pushing the local takeback initiatives in California.